The Search for Data on When to Start Treatment for HIV Infection
Author(s) -
Michael D. Hughes,
Heather Ribaudo
Publication year - 2008
Publication title -
the journal of infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.69
H-Index - 252
eISSN - 1537-6613
pISSN - 0022-1899
DOI - 10.1086/586712
Subject(s) - medicine , adverse effect , intensive care medicine , asymptomatic , human immunodeficiency virus (hiv) , quality of life (healthcare) , drug , clinical trial , antiretroviral therapy , immunology , viral load , pharmacology , nursing
clinical events at higher CD4+ cell counts; the negative impact of side effects on qual- ity of life as well as the occasional occur- rence of life-threatening adverse effects, including ones that have been associated with long-term use of ART (such as my- ocardial infarction); and the inconve- nience of drug regimens, leading to re- duced adherence, an increased risk of drug resistance, and limitations on future drug options. Revisiting these issues, Phillips et al. (5) recently concluded that advances in drug development and an improved un- derstanding of the durability and adverse effects of specific drugs has led to renewed interest in the possibility that initiation of ART at CD4+ cell counts 1200 cells/mL might be preferable.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom